Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472353 · ClinicalTrials.gov registry record · Phase 2
Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
A Phase 2 study, sponsored by Avera McKennan Hospital & University Health Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02472353 is a Phase 2 study that was terminated before completion, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 30 participants.
The verdict
NCT02472353, a Phase 2 study, was terminated before completion, sponsored by Avera McKennan Hospital & University Health Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in left ventricle ejection fraction (LVEF).
Interventions
- DRUG Doxorubicin
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-05-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02472353
The ClinicalTrials.gov registry entry for NCT02472353 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avera McKennan Hospital & University Health Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT02472353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02472353 about?
NCT02472353 is a clinical study titled "Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer". The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in left ventricle ejection fraction (LVEF).
What is the current status of trial NCT02472353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2018-05-23.
What interventions are being tested in trial NCT02472353?
The interventions under investigation include: Doxorubicin (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT02472353?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.